Anatomy of an Epidemic: Psychiatric Drugs and the Astonishing Rise of Mental Illness in America by Robert Whitaker, Ethical Human Psychology and Psychiatry, Volume 7, Number I , Spring 2005 Mon, 29 Aug 2005 Some uncritical promoters of psychiatry and its current biological treatment paradigm have declared that the introduction…
Epidemiologist Says Most Published Research Findings Are False – Psychiatrist Addresses Credibility Crisis Sat, 8 Oct 2005 An article published in PLoS Medical (an Open Access Peer Reviewed Medical Journal) by an epidemiologist who holds academic positions on both sides of the Atlantic–at the University of Ioannina (Greece) and Tufts…
“The scariest thing is that nobody knows” risks of depression drugs for children Mon, 10 May 2004 Forest Laboratories, manufacturer of the antidepressant, Celexa / Lexapro, is the latest manufacturer to issue warnings (April 2004) about the possibility that “patients with major depressive disorder, both adult and pediatric, may experience…
Two-thirds foster care children in Mass on psych drugs_Globe Psychiatry: Soviet Experience–American Fallacy Wed, 11 Aug 2004 The Boston Globe reports that 2/3 of children in state care in Massachusetts are being “treated” for mental illness with psychotropic drugs. Marie Parente, a legislator, and parents call for disclosure of “how…
Elliott Spitzer walks away from prosecuting coporate crimes Sat, 25 Dec 2004 “After nearly three years of high-profile prosecutions of investment banks, mutual funds and insurance companies, Attorney General Eliot Spitzer of New York said yesterday that he is ready to cede those investigations to federal regulators.” Whatever Eliot Spitzer…
FDA Bad Faith – Daniel Troy’s pre-emption defense – Nat’l Law Journal Fri, 26 Mar 2004 Federal regulations require drug label warnings if there is “reasonable evidence” of a link between adverse effects and drug action. An article in the National Law Journal shows how s FDA’s chief counsel, Daniel…
Suicide in Psych Drug Trials: FDA Orwelian doublespeak – Insight Magazine Date: Mon, 14 Oct 2002 Insight Magazine’s interview with Dr. Thomas Laughren, team leader for the neuropharmachological drug-products division of the FDA, shows that FDA was caught off guard when Dr. Arif Khan independently analyzed FDA’s data revealing that…
Medscape Cites AHRP Concerns Re: New Law Mandates More Testing of Drugs in Children Wed, 17 Dec 2003 Medscape Medical News reports about passage of the Pediatric Research Equity Act (PREA) which replaces FDA’s Pediatric Rule. The Pediatric Rule was struck down by a Federal court in Oct. 2002 because…
FDA reviews depression drugs–Intense or Cautious? WashPost/ NYT/ Herald Wed, 29 Oct 2003 The Washington Post correctly reports: “The association between antidepressants, particularly the selective serotonin reuptake inhibitors (SSRIs), and suicide has been controversial since the first SSRI, Prozac, came on the market in the late 1980s.” But stakeholders in…
Letter from David Healy, MD to Peter J. Pitts Executive Summary of suicidal evidence not addressed by FDA In the light of Traci Johnson’s death on February 7th 2004, will FDA obtain Pfizer’s entire folder on the 1982 Hindmarch study in which healthy volunteers were given Zoloft, and make a…
Infomail 2004 News Stories on Human Research Protection and Commentary by Vera Hassner Sharav Dec 31: FDA to review “missing” drug company documents Dec 30: Family of Woman Killed by AIDS Drug Test Sues Doctors, Manufacturer Dec 30: Doctors, Too, Ask: Is This Drug Right? Dec 29: Bill would shield…
Senate Finance Committee Investigating FDA brain stimulation device approval – WSJ Thu, 19 May 2005 Another major scandal is erupting about FDA’s approval decisions that contradict its medical officer’s safety concerns. The Senate Finance Committee is investigating what led the FDA to suddenly reverse its disapproval of Cyberonics’ brain stimulation…
